GPN2 Inhibitors
GPN2 Inhibitors are chemical compounds that interfere with cellular processes and signaling pathways essential for the functional activity of GPN2, a protein involved in nucleocytoplasmic transport and cell cycle progression. Alisertib, an Aurora kinase A inhibitor, disrupts cell cycle progression, thereby potentially leading to decreased GPN2 activity as GPN2 is necessary for cell division. Similarly, the mTOR inhibitors Rapamycin, AZD8055, and Torin 2, curtail cell growth and proliferation, processes in which GPN2 is implicated. The presence of these compounds leads to a reduction in the pathways that GPN2 facilitates, diminishing its activity. Cycloheximide's mechanism of inhibiting protein synthesis directly affects the production of GPN2, ensuring its activity is decreased by limiting its synthesis. Shikonin, targeting pyruvate kinase M2, disrupts cellular energy production, which in turn could reduce the energy-dependent functions of GPN2, such as its role in nucleocytoplasmic transport.
Other GPN2 inhibitors interferes with various aspects of nucleic acid processing and protein folding, indirectly affecting GPN2 functionality. Brefeldin A, by inhibiting ARF, disrupts vesicle trafficking, which is crucial for the transport functions that GPN2 mediates. Triptolide's inhibition of RNA polymerase leads to a reduction in RNA synthesis, thereby diminishing GPN2's involvement in transporting RNA molecules. Geldanamycin's binding to Hsp90 affects the chaperone activity necessary for the proper folding and function of various proteins including GPN2, leading to a decrease in its activity. Mitoxantrone, a type II topoisomerase inhibitor, by hindering DNA synthesis and repair, may indirectly decrease GPN2's activity, which is relevant during DNA replication. Collectively, these compounds utilize diverse biochemical mechanisms to diminish the functional activity of GPN2 by targeting the cellular pathways and processes it is involved in.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. GPN2 is involved in the cell cycle, and the inhibition of Aurora kinase A by Alisertib can disrupt proper cell cycle progression, potentially leading to decreased GPN2 activity since GPN2 function is required for efficient cell cycle progression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, Rapamycin can impair cell growth and proliferation pathways that are necessary for GPN2 function, as GPN2 is implicated in ribosome biogenesis and protein translation within the cell growth context. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is involved in vesicle trafficking. As GPN2 is essential for nucleocytoplasmic transport, the inhibition of ARF by Brefeldin A disrupts vesicle formation and transport, indirectly diminishing GPN2's functional role. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis, thus impairing the synthesis of proteins including GPN2. This diminishes GPN2 activity since it cannot be synthesized. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a selective inhibitor of mTOR kinase activity, leading to the inhibition of both mTORC1 and mTORC2 signaling pathways which are crucial for cell proliferation and survival where GPN2 is implicated in the nucleocytoplasmic transport of the molecules involved. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is a diterpene triepoxide that has been shown to inhibit RNA polymerase I, II, and III, leading to a decrease in RNA synthesis and potentially diminishing GPN2 activity due to its role in nucleocytoplasmic transport of RNA molecules. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin binds to Hsp90 and inhibits its chaperone activity. GPN2 may require Hsp90 for proper folding and function, and the inhibition by geldanamycin could indirectly lead to decreased GPN2 activity. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone is a type II topoisomerase inhibitor that disrupts DNA synthesis and repair. Inhibiting DNA synthesis can indirectly decrease GPN2 activity, as GPN2 is involved in the nucleocytoplasmic transport which is important during DNA replication and cell cycle progression. | ||||||